Taiwan's Adimmune targets June start for mass production of bird flu vaccine

Taiwan-based Adimmune is preparing to start mass production of its H7N9 bird flu vaccine. The company is targeting a June start date for production and expects to manufacture 3 million doses a month when at full capacity. At this stage it is unclear if the Taiwanese government would buy the vaccine. Adimmune is continuing development nonetheless, to be ready to produce the vaccine if required. A Phase II trial of the vaccine is due to begin next month. News

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.